Kestra Medical Technologies, Ltd. Completes Initial Public Offering with Full Exercise of Underwriters' Over-Allotment Option

Kestra Medical Technologies Ltd Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Initial Public Offering

Hong Kong, March 14, 2025 - Kestra Medical Technologies Ltd ("Kestra" or the "Company"), a leading medical device company focused on developing innovative solutions for the treatment of cardiovascular diseases, today announced that the underwriters have fully exercised their over-allotment option in connection with the Company's initial public offering ("IPO").

As a result, the total number of shares issued in the IPO has increased to 15,000,000 shares, with gross proceeds of approximately HK$150 million (approximately USD 19.3 million). The IPO was priced at HK$10.00 per share.

The additional shares were issued to the public at the same price as the initial offering, and the gross proceeds from the over-allotment option will be used to support the Company's continued expansion of its commercial and clinical development efforts.

"We are thrilled to have successfully completed our IPO and to have received such strong support from investors," said Dr. [Name], CEO of Kestra. "The additional capital will enable us to accelerate our growth strategy and further our mission to improve patient outcomes through the development of innovative medical devices."

The shares are listed on the Main Board of the Hong Kong Stock Exchange under the stock code "1988".

About Kestra Medical Technologies Ltd

Kestra Medical Technologies Ltd is a leading medical device company focused on developing innovative solutions for the treatment of cardiovascular diseases. The Company's products are designed to improve patient outcomes and reduce healthcare costs. Kestra is headquartered in Hong Kong and has a strong team of professionals with expertise in medical device development, regulatory affairs, and commercialization.